Bayesian estimation of cost-effectiveness ratios from clinical trials

Health Economics

Volumn 8, Issue 3, 1999, Pages 191-201

  Heitjan, Daniel F ^a,b   Moskowitz, Alan J ^a   Whang, William ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE   (United States)

Author keywords

Bayesian inference; Clinical trials; Confidence intervals; Cost effectiveness ratios; Net health benefit

Indexed keywords

BAYES THEOREM; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; PROBABILITY; REVIEW; SIMULATION;

BAYES THEOREM; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DRUG EVALUATION; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; LIKELIHOOD FUNCTIONS; MODELS, ECONOMETRIC; VALUE OF LIFE;

EID: 0032943122     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1050(199905)8:3<191::AID-HEC409>3.0.CO;2-R     Document Type: Review

References (17)

1. Briggs, A.H., Wonderling, D.E. and Mooney, C.Z. Pulling cost-effectiveness analysis up by its boot-straps: a non-parametric approach to confidence interval estimation. Health Economics 1997; 6: 327-340.
2. Chaudhary, M.A. and Stearns, S.C. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Statistics in Medicine 1996; 15: 1447-1458.
3. Laska, E.M., Meisner, M. and Siegel, C. Statistical inference for cost-effectiveness ratios. Health Economics 1997; 6: 229-242.
4. Manning, W.G., Fryback, D.G. and Weinstein, M.C. Reflecting uncertainty in cost-effectiveness analysis. In: Gold, M.R., Siegle, J.E., Russell, L.B. and Weinstein, M.C. (eds.) Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996.
5. Obenchain, R.L. Issues and algorithms in cost-effectiveness inference. Biopharmaceutical Report 1997; 5: 1-7.
6. O'Brien, B.J., Drummond, M.F., Labelle, R.J. and Willan, A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Medical Care 1994; 32: 150-163.
7. Polsky, D., Glick, H.A., Willke, R. and Schulman, K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Economics 1997; 6: 243-252.
8. Heitjan, D.F., Moskowitz, A.J. and Whang, W. Problems with interval estimates of the incremental cost-effectiveness ratio. Medical Decision Making 1999; in press.
9. Heitjan, D.F. Fieller's method and net health benefits. Submitted for publication.
10. Berry, D.A. Statistics: a Bayesian perspective. Belmont, CA: Duxbury Press, 1996.
11. Box, G.E.P. and Tiao, G.C. Bayesian inference in statistical analysis. Reading, MA: Addison-Wesley, 1973.
12. Gelman, A., Carlin, J., Stern, H. and Rubin, D.B. Bayesian data analysis. London: Chapman & Hall, 1995.
13. Stinnett, A.A. and Mullahy, J. The negative side of cost-effectiveness analysis. Journal of the American Medical Association 1997; 277: 1931-1932.
14. Stinnett, A.A. and Mullahy, J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making 1998; 18: S68-S80.
15. Fisher, C.J., Slotman, G.J., Opal, S.M., et al. Initial evaluation of human recombinant interleukin-1 receptor agonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Critical Care Medicine 1994; 22: 12-21.
16. Gordon, G.S., Fisher, C.J., Slotman, G.J. et al. Cost-effectiveness of treatment with interleukin-1 receptor agonist (IL-1ra) in patients with sepsis syndrome. Clinical Research 1992; 40: 254A.
17. van Hout, B.A., Al, M.J., Gordon, G.S. and Rutten, F.F.H. Costs, effects and C/E-ratios alongside a clinical trial. Health Economics 1994; 3: 309-319.